DV
Dividend Vision

XNCR Stock — Xencor Inc

Xencor Inc (XNCR)

Updated October 16, 2026.

XNCR is a Stock. Total return is 174.0% over the past 12.9 years, 254.3 points behind SPY at 428.3%.

Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibodies to treat cancer and autoimmune diseases. The company markets Ultomiris for conditions including atypical hemolytic uremic syndrome and generalized myasthenia gravis, and Monjuvi for relapsed or refractory diffuse large B-cell lymphoma, while advancing a pipeline of bispecific antibodies and other candidates across multiple therapeutic areas. The company does not currently have an established distribution schedule.

XNCR performance versus SPY

Price and return data through 2026-10-16.

Total return is 174.0% over the past 12.9 years, 254.3 points behind SPY at 428.3%. Over the past year its total return — price change plus distributions reinvested — is 52.8%. Its deepest 1-year drawdown was 42.6%.

WindowTotal returnCAGR
1M-3.6%—
3M52.8%—
6M83.5%—
YTD49.3%—
1Y52.8%—
2Y CAGR—3.10%
3Y CAGR—6.40%
5Y CAGR—-9.90%
10Y CAGR—1.20%
Since inception (12.9 years)174.0%8.20%

XNCR key facts

Asset type
Stock
Asset class
Equity
Inception date
12/03/2013
Distribution frequency
None
Last close
$22.85 (as of 2026-10-16)
Market cap
$1,698,975,121
Average volume
1129982.0
Beta
0.896
Payout ratio
0.0%
Forward P/E
68.0272
EPS
$-2.16

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

XNCR risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 42.6%.

Who may consider XNCR — and who may not

It is a weaker fit for investors who need monthly cash flow (XNCR does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on XNCR

Tagged: Healthcare.

Frequently asked questions

Does XNCR pay monthly?

No. XNCR does not currently distribute.

When does XNCR pay a dividend?

XNCR does not currently distribute.

How has XNCR performed?

Total return is 174.0% over the past 12.9 years, 254.3 points behind SPY at 428.3%. Over the past year its total return — price change plus distributions reinvested — is 52.8%. Its deepest 1-year drawdown was 42.6%.

DividendVision analysis is generated from public SEC filing data and may not capture every change. Review the original filing for complete information.